The total RNA sequencing market was estimated at $2,368 million ($2.37 billion) in 2021, with roughly 3/4 of revenues from consumables. The following table and graph present the estimates for 2021. This according to a new report from Kalorama Information on RNA Sequencing markets.
The sequencing market has continued to provide powerful tools that hold the promise of bringing major changes to healthcare in the near future. In the last decade, explosive growth has occurred in terms of product introductions, new applications, and the end-user labs rushing to participate in these new areas. Now market growth is more related to a shift in the technology applied in life science applications.
“In recent years, the use of microarrays for RNA expression analysis has dropped greatly as RNA sequencing has risen to replace and outshine it,” the report said.
Similar to quantitative reverse transcription-PCR (q-RT-PCR) which has been the gold standard, there is a need for pre-defined probes which creates one of the major weaknesses of microarrays, and RNA-seq provides a number of advantages including:
• improved sensitivity and dynamic range
• ability to study species without reference
• measurement of focal changes (such as single nucleotide variants, insertions and deletions)
• detection of different transcript isoforms, splice variants and chimeric gene fusions (including previously unidentified genes and/or transcripts)
Major companies in the market include: Illumina, Thermo Fisher Scientific, New England Biolabs, 10X Genomics, Agilent Technologies, Takara BIo, Oxford Nanopore Technologies, Tecan’s Nugen, Pacific Biosciences and Standard Biotools. The report profiles these companies and provides market share.